Interim Data Presentation From the ADVANCED - 2 Trial of TARA - 002 in BCG - Na ve NMIBC Patients Society Of Urologic Oncology Annual Meeting December 2025 2 Statements contained in this presentation regarding matters th
Wednesday, December 3, 2025 1 min read
Key Takeaway: The article discusses the interim data presentation from the ADVANCED - 2 trial involving TARA-002, which targets BCG-naive NMIBC patients. The presentation was made during the Society of Urologic Oncology Annual Meeting in December 2025. Key opinion leader Dr. Neal Shore contributed to the discussion, highlighting the potential implications of the results. This data presentation may influence future treatment options in this patient demographic.
Market Sentiment Analysis
POSITIVE FACTORS
Positive interim data from the ADVANCED - 2 trial.
Focus on BCG-naive NMIBC patients indicates a targeted approach.
Full Press Release Details
Interim Data Presentation From the ADVANCED - 2 Trial of TARA - 002 in BCG - Na ve NMIBC Patients Society Of Urologic Oncology Annual Meeting December 2025
TARA - 002 Lyophilized, Inactivated Group A Streptococcus pyogenes
KOL DISCUSSION Neal Shore, MD Medical Director, Carolina Urologic Research Center
Frequently Asked Questions
What was presented at the 2025 Society of Urologic Oncology meeting?
Interim data from the ADVANCED - 2 trial of TARA - 002 was presented.
What is TARA - 002?
TARA - 002 is a lyophilized, inactivated form of Group A Streptococcus pyogenes.
Who discussed the trial data?
Dr. Neal Shore, Medical Director of Carolina Urologic Research Center, discussed it.
Who are the patients focused on in the ADVANCED - 2 trial?